Investment
Features
FeesSafety
Academy
More
Pluang+

Prospector Metals confirms high-grade gold over 100m at Yukon ML Project with 100 holes drilled in 2026.

Market News
06 Oct 2026
Newsfile Corp
View Source
Bullish
Prospector Metals confirms high-grade gold over 100m at Yukon ML Project with 100 holes drilled in 2026.

Prospector Metals completed a fully funded 2026 drill program at its ML Project in Yukon, drilling 100 holes totaling 20,980 meters. Results from the TESS Zone confirm high-grade gold mineralization over at least 100 meters along a 400-meter structural corridor, with multiple high-grade plunging zones identified. Significant assays include 41.34 g/t gold over 7.81m and 130.77 g/t gold over 2.25m in hole ML26-56. The program also found accompanying copper and silver mineralization. Assays for 84 holes are pending, and exploration continues to target new zones for 2027. This progress supports the potential for a structurally controlled gold system similar to those in the Canadian Shield.

Prospector Metals' high-grade gold assays highlight ongoing exploration progress. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 06, 2026 18:11 WIB: Among 38 priced US stocks, 19 rose and 13 fell today. Notable movers include BHP Billiton Limited at USD 87.49 (+0.76%), Freeport-McMoRan Inc at USD 73.12 (+0.69%), and Aspen Aerogels Inc at USD 5.64 (-0.79%).

More News

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...

Analyst Insights
Neutral
3 hours ago
OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial testing urcosimod for neuropathic corneal pain, a severe eye condition with no FDA-approved treatment. The trial has begun in the US and will expand to Europe, with patients rec...

Market News
Bullish
4 hours ago
Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street analysts have reached a rare consensus on five dividend stocks yielding 5% or more, seen as strong buys for dependable passive income. These stocks—Amcor, Energy Transfer, International Paper, Mid-America Apartment Communities, and Verizo...

Analyst Insights
Bullish
4 hours ago
OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

Crypto exchange OKX has maintained its $25 billion valuation in a new funding round featuring Qube Research & Technologies (QRT), Circle, Ripple, and Standard Chartered’s SC Ventures. The fresh capital will help OKX enhance its market infrastructure ...

Market News
Bullish
4 hours ago
Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta has started testing a new Facebook user experience in India that opens the app directly into full-screen video, highlighting Reels. This test aims to create a more immersive, video-centric experience and follows Meta's broader strategy to priori...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App